Clinical trials: Pharmacogenomic Testing
Metastatic Colorectal Cancer
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer).
- Trial name
- EVIDENT (NCT05725200)
- Testing
- Alectinib, Cetuximab, Crizotinib
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Pharmacogenomics, Polypharmacy
Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services.
- Trial name
- NCT05053815
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Tabula Rasa HealthCare
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Machine Learning, Prediction Models
Timely Ordering of Pharmacogenetic Testing
The goal of this trial is to learn if a machine learning (ML) model can help optimize drug therapy in the pediatric population. The main question[s] it aims to answer are whether a machine learning model predicting receipt of a…
- Conditions
- Machine Learning, Prediction Models, Pediatrics, Precision Medicine
- Trial name
- NCT06902688
- Testing
- ML-based intervention
- Where
- Canada
- Volunteers
- 275 people
- Sponsor
- The Hospital for Sick Children
Antidepressants Causing Adverse Effects in Therapeutic Use
Pharmacogenomic Testing in Primary Care
This is a 6-month randomized, wait-listed, controlled pilot trial conducted in 6 department of family medicine (DFM) clinics at the University of Michigan (UM).
- Trial name
- NCT03270891
- Testing
- PGx test
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan
Pharmacogenetic Testing, Elderly
Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly
Pharmacist-led pharmacogenomics (PGx) clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by CareKinesis d/b/a Tabula Rasa…
- Conditions
- Pharmacogenetic Testing, Elderly, Opioid Use, Pain
- Trial name
- NCT04971902
- Testing
- Pharmacogenetic Test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Tabula Rasa HealthCare
Pharmacogenetic Testing
Pharmacogenetic Testing in Primary Care
The purpose of this study is to further integrate pharmacogenetic (PGx) testing into clinical practice by educating physicians about pharmacogenetics and offering testing to their patients.
- Trial name
- NCT01600846
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Depressive Disorder, Major, Depression
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder
Evidence exists supporting the ability of genetic variations to influence patient drug response and side effects. Previous studies utilizing an open-label design have shown significant improvement in major depressive disorder…
- Conditions
- Depressive Disorder, Major, Depression, Depressive Disorder
- Trial name
- NCT02466477
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- 14 sites in Canada
- Volunteers
- 542 people
- Sponsor
- Assurex Health Inc.
Pharmacogenomic
Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)
Current providers' standard operating procedures on pharmacogenomic testing patients
- Trial name
- NCT03322189
- Testing
- pharmacogenomic
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Data Collection Analysis Business Management
Pharmacogenetic Testing
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects.
- Trial name
- MedOPT (NCT03468309)
- Testing
- Genecept Assay and G-DIG decision tool
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Adverse Drug Reaction
PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions
PREPARE is an international, prospective, multi-center, open, randomized, cross-over implementation study assessing the impact of pre-emptive pharmacogenomic testing, of a panel of actionable pharmacogenomic variants, on adverse…
- Trial name
- PREPARE (NCT03093818)
- Testing
- Pharmacogenomic testing
- Where
- 7 sites in Austria, Greece and 5 more
- Volunteers
- 6,950 people
- Sponsor
- J.J.Swen
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04067960
- Testing
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Pharmacogenetics, Medication Therapy Management
Medication Therapy Management With Pharmacogenetic Testing
This study aims to investigate the benefit and feasibility of providing pharmacogenetic (PGx) testing as part of a standard medication therapy management (MTM) session for patients taking multiple medications, a high-risk…
- Trial name
- NCT01970774
- Testing
- MTM with PGx
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Duke University
Pharmacogenetic Testing
Pharmacogenetic Testing at Community Pharmacy
The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription.
- Trial name
- OffiGene (NCT06210321)
- Testing
- Prescription of escitalopram using pharmacogenetic testing
- Volunteers
- 270 people
- Sponsor
- Chantal Csajka
Major Depressive Disorder
Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major…
- Trial name
- PGX-AMG (NCT02443584)
- Testing
- pharmacogenetic testing
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Schizophrenia, Schizoaffective Disorder
Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment With Antipsychotics
Antipsychotics are approved to treat several conditions, including Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, and Major Depressive Disorder among others.
- Trial name
- NCT02573168
- Testing
- GeneSight Psychotropic (GEN), Enhanced-GeneSight Psychotropic (E-GEN), Treatment as Usual (TAU)
- Where
- Canada
- Volunteers
- 103 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Major Depressive Disorder, Depression
Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder
This study aims to determine whether the GeneSight Psychotropic test can result in better treatment outcomes for patients with treatment-naive major depressive disorder
- Conditions
- Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode
- Trial name
- NCT03537547
- Testing
- GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Pharmacogenetic Testing to Determine Pharmacological Treatment in PTSD
Personalized Pharmacotherapy Using Pharmacogenetics in Veterans
This study is an observational clinical trial aimed at to evaluate the use of pharmacogenetic testing (PGx) for mental health treatment in members and Veterans of the CAF and RCMP patient population as well as the attitudes of…
- Trial name
- PGx (NCT06335043)
- Testing
- Pharmacogenetics Testing
- Where
- Canada
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pharmacogenetics
Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting
This study aims to compare patient use of and satisfaction with community pharmacist-delivered pharmacogenetic (PGx) testing delivered along or as part of a medication therapy management (MTM) service.
- Trial name
- NCT02937545
- Testing
- Medication Therapy Management, Pharmacogenetic testing
- Where
- United States
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Duke University
Cancer
Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy
This study will be evaluating patients suspected to carry DPYD or UGT1A1 variants based off of Michigan Genomics Initiative (MGI) results.
- Trial name
- NCT05583422
- Testing
- DPYD or UGT1A1 variants
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center